Amarin Corp‘s patent outlines a method to reduce heart failure risk in patients on statin therapy by administering 1 to 4 grams of eicosapentaenoic acid ethyl ester daily. The claim specifies a regimen for subjects with specific triglyceride and EPA levels to enhance their EPA levels effectively. GlobalData’s report on Amarin Corp gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Amarin Corp, Cancer treatment biomarkers was a key innovation area identified from patents. Amarin Corp's grant share as of June 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Reducing heart failure risk using eicosapentaenoic acid
The granted patent US11986452B2 outlines a method aimed at reducing the risk of heart failure in subjects with specific baseline triglyceride and eicosapentaenoic acid (EPA) levels. The primary intervention involves administering approximately 4 grams of ethyl icosapentate daily to individuals who have a baseline triglyceride level of at least 135 mg/dL and an EPA level of about 26 µg/mL. The treatment is designed to elevate the subject's EPA level to a minimum of 104 µg/mL, with further claims suggesting that this level can be increased to between 104 µg/mL and 175 µg/mL, or even higher. The patent also specifies that the method can be applicable to subjects experiencing new heart failure, including those requiring hospitalization, and emphasizes the potential to reduce risks associated with cardiovascular events such as myocardial infarction and stroke.
Additionally, the patent details the composition of ethyl icosapentate, which should constitute at least 90% to 96% of the omega-3 fatty acids in the pharmaceutical formulation. The claims extend to subjects with established cardiovascular disease or those at high risk for such conditions, particularly if they have additional risk factors. The method may also be used in conjunction with statin therapy to further mitigate cardiovascular risks. Overall, the patent presents a targeted approach to managing heart failure risk through specific dietary supplementation, highlighting the importance of monitoring EPA levels in at-risk populations.
To know more about GlobalData’s detailed insights on Amarin Corp, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
